Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples